Phragma Therapeutics develops targeted therapies to restore blood-brain barrier integrity for neurological and neurodegenerative diseases. Their focus is on conditions such as Alzheimer's and Parkinson's, aiming to strengthen central nervous system barriers.
Funding
Funding not disclosed
Founders
Product
Problem
Neurological and neurodegenerative diseases, such as Alzheimer's and Parkinson's, are often exacerbated by a compromised blood-brain barrier (BBB). A weakened BBB can allow harmful substances to enter the central nervous system, accelerating disease progression and hindering the effectiveness of therapeutic interventions.
Solution
Phragma Therapeutics is developing targeted therapies designed to restore and strengthen the integrity of the blood-brain barrier. Their approach aims to modulate the BBB, preventing the influx of detrimental elements into the central nervous system. By reinforcing this critical barrier, Phragma Therapeutics seeks to slow the advancement of neurological and neurodegenerative conditions and improve patient outcomes. The company's therapeutic strategies focus on fortifying the BBB to protect the brain from further damage.
Target Audience
The primary target audience includes individuals suffering from neurological and neurodegenerative diseases, such as Alzheimer's and Parkinson's, and the healthcare providers who treat them.
Features
- Development of CNS therapeutics specifically designed to modulate the blood-brain barrier.
- Targeted approach to address the underlying causes of BBB breakdown in neurological diseases.